InvestSMART

AdAlta Limited (ASX: 1AD) - Share Price

- Current share price for 1AD : $0.004

AdAlta Limited (1AD) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical stage biotechnology company and is involved in the discovery and development of next generation cell and protein-based therapeutics.

1AD General Information +

ASX Code 1AD
Website http://www.adalta.com.au
Industry/Sector Biotechnology
Market Cap ($M) 11
1AD Share Price $0.004
Day High $0.004
Day Low $0.004
Last Close $0.004
1AD Share Price Movement - ( No change )
Prices as at 16:40, 25 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

AdAlta Limited (1AD) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from AdAlta Limited (1AD) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

AdAlta Limited (1AD) price-sensitive announcements

1AD - Preliminary Final Report
AdAlta Limited released its Preliminary Final Report for the year ended 30 June 2026, anno
AdAlta Limited (1AD)
21 Aug 2026 | 4:54 PM
1AD - EW-001 IIT study overall survival update
AdAlta Limited has provided an update on the Investigator Initiated Trial (IIT) of its lea
AdAlta Limited (1AD)
10 Aug 2026 | 9:18 AM
1AD - 2 year survival milestone for EW-001 patient
AdAlta Limited (ASX:1AD) reported a significant milestone in the ongoing Investigator Init
AdAlta Limited (1AD)
5 Aug 2026 | 8:26 AM
1AD - Quarterly Appendix 4C and Activities Report
AdAlta Limited, an Australian biotechnology company, provided its quarterly Appendix 4C an
AdAlta Limited (1AD)
29 Jul 2026 | 9:23 AM

AdAlta Limited (1AD) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
AdAlta Limited (1AD)
ORDINARY FULLY PAID
 Health Care $11 US FDA grants EW-001 pre-IND meeting 23 Sep 2026 8:17AM $0.004 $0.004 fallen by 0%
AdAlta Limited (1AD)
ORDINARY FULLY PAID
 Health Care $11 Oribiotech deal validates AdAlta manufacturing strategy 18 Sep 2026 9:52AM $0.003 $0.004 risen by 16.67%
AdAlta Limited (1AD)
ORDINARY FULLY PAID
 Health Care $11 CAR-TCR Summit poster 15 Sep 2026 8:22AM $0.003 $0.004 risen by 16.67%
AdAlta Limited (1AD)
ORDINARY FULLY PAID
 Health Care $11 Bilingual BIOSeedin Investor Presentation 10 Sep 2026 9:49AM $0.003 $0.004 risen by 16.67%
AdAlta Limited (1AD)
ORDINARY FULLY PAID
 Health Care $11 BZDS1901 special access scheme launch in China 2 Sep 2026 9:30AM $0.003 $0.004 risen by 16.67%
AdAlta Limited (1AD)
ORDINARY FULLY PAID
 Health Care $11 Appendix 4G and Corporate Governance Statement 21 Aug 2026 5:00PM $0.004 $0.004 fallen by 0%

1AD Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$4.68 -$0.20 -66.70% 0.00 0.00 0.00% 0.0%
2025A -$4.50 -$0.70 -24.20% 0.00 0.00 0.00% 0.0%
2024A -$5.38 -$0.90 -28.90% 0.00 0.00 0.00% 0.0%

1AD Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
AdAlta Limited (1AD) $11M -0.6667 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
CSL Limited (CSL) $85,957M 0.7309 -0.4440 0.0545 11.0969 19.9585 18.9263 2.37% 2.32% 2.40%
Mesoblast Limited (MSB) $2,844M -0.4380 0.0000 0.0000 0.0000 0.0000 347.6190 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $2,862M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,350M -1.3893 0.0000 -0.2777 0.0000 174.1150 241.0413 0.00% 0.00% 0.00%

1AD Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 35.00 0.00
Market 0.33 13.80 1.17 0.79
Sector 0.63 30.70 2.72 1.90

1AD Directors

Name Position Start Date
Dr Timothy Oldham Managing Director, Chief Executive Officer 8 Oct 2019
Dr Paul MacLeman Non-Executive Chairman, Non-Executive Director 16 Apr 2015
Mr Fadi Diab Non-Executive Director 18 Mar 2026
Ms Michelle Burke Non-Executive Director 20 Nov 2024

AdAlta Limited (1AD) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
28 Oct 2025 OLDHAM, Timothy Buy Indirect Shares 2,500,000 $0.004 $8,750.000
4 Jun 2025 MACLEMAN, Paul Issued Indirect Shares 71,072 $0.003 $213.220
4 Jun 2025 OLDHAM, Timothy Issued Indirect Shares 11,666,666 $0.003 $35,000.000

See all changes in directors' interest & trades for AdAlta Limited (1AD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

1AD Management

Name Position
Cameron Jones Chief Financial Officer,Company Secretary

1AD Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in AdAlta Limited (1AD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
166,108,388 (14.92%) Stuart Morris
92,345,364 (8.30%) HSBC Custody Nominees (Australia) Limited
66,666,667 (5.99%) Chunyan Niu

1AD Calendar of Events

Date Event
20 August 2027 Report (Annual)
20 August 2027 Report (Prelim)
19 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.